UK Innovation & Science Seed Fund
VC Fund
Harwell, United Kingdom
UK Innovation & Science Seed Fund is a VC fund in Harwell focused on Biotechnology and Health Care. The UK Innovation & Science Seed Fund is backed by the Department for Business, Energy and Industrial Strategy and the Fund’s partners are 9 publicly funded research bodies, including STFC, BBSRC, NERC and Dstl. The Fund is independently managed by venture capital specialist Midven. They help build companies from great science developed in laboratories, science and technology campuses and synthetic biology. They hold investments in some of the UK’s most innovative companies, in areas as diverse as novel antibiotics, research into Alzheimer’s disease, “green” chemicals and airport security.
- Total investments:
- 151
- Last investment:
- Lead investor:
- 32%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries UK Innovation & Science Seed Fund invests in
Stages UK Innovation & Science Seed Fund invests in
Countries UK Innovation & Science Seed Fund invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $582k–$5.9M
- Venture - Series Unknown
- $1M–$6.7M
Investment Focus
Industry
- Biotechnology 43 (28%)
- Health Care 24 (16%)
- Medical 20 (13%)
- Manufacturing 17 (11%)
- Software 13 (9%)
Stage
- Seed 74 (49%)
- Venture - Series Unknown 11 (7%)
- Funding Round 10 (7%)
- Series A 8 (5%)
- Pre-Seed 6 (4%)
Country
- United Kingdom 90 (60%)
- United States 3 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Alexander Leigh
Investment Director
|
Investment Director | Total investments: 13 | Find email | |
Andrew Muir
Investment Director & Fund Principal
|
Investment Director & Fund Principal | Total investments: 8 | Find email | |
Mark White
Director
|
Director | Total investments: 4 | Find email | |
Oliver Sexton
Investment Director
|
Investment Director | Total investments: 17 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| SilVia Bio develops technologies to analyze and optimize mammalian cell factories used in biomanufacturing. The company focuses on identifying critical parameters that limit bioproduction yield and product quality in cell systems such as CHO and HEK cells. Its platform provides cell profiling services that generate interpretable data on manufacturing-relevant bottlenecks. Based on these insights, SilVia Bio designs and supplies precision media additives formulated to address specific rate-limiting cellular processes. The offerings are intended for biopharmaceutical and biomanufacturing teams seeking to improve titre, cell performance, and consistency in production processes. SilVia Bio also collaborates with industrial partners to apply its platform within real manufacturing environments. | $4M / Seed / Oct 15, 2026 | ||
| StandardX is a deep-tech company building the isotope refinery powered by a scalable, compact particle accelerator platform. | $13.3M / Seed / Sep 23, 2026 | ||
| Intelligent Mass Spec Solutions develops diagnostic technology that combines clinical expertise, high quality mass spectrometry and machine learning. The company focuses on detecting a specific chemical signature in urine that is diagnostic of adrenocortical carcinoma and other adrenal tumours. Its approach uses data from large clinical studies to derive algorithms that distinguish malignant from benign adrenal tumours. Patients provide simple home urine samples that are sent for laboratory analysis, avoiding multiple imaging procedures and hospital visits. The analytical results are processed to identify the relevant urinary steroid metabolite patterns. A structured diagnostic report is then delivered to clinicians to inform follow-up investigations and treatment decisions. Intelligent Mass Spec Solutions aims its services at healthcare providers who manage patients with incidentally discovered adrenal tumours. | $1.5M / Seed / Sep 22, 2026 | ||
| KVector creates communication and sensing solutions with high gain and efficiency from X-band to sub-terahertz bands and beyond. Modern antenna systems are built by KVector. | $5.1M / Seed / Sep 09, 2026 | ||
| Singular Machines is an engineering automation company that provides solutions to engineering issues. | Pre-Seed / Aug 03, 2026 | ||
| HALO X-ray Technologies has been spun out of the Imaging Science Group at Nottingham Trent University and the Cranfield Forensic Institute at Cranfield University. We are developing commercially-focused OEM X-ray diffraction solutions based on novel and patented Focal Construct Technology that provides platform capability across a wide range ofapplication areas. Their initial focus lies in the development of HALO solutions for the aviation security and the medical systems markets. We have strong ties to the aviation sector through a long and prestigious research and development programme that has previously realised novel divergent beam X-ray technology (developed and marketed through various incumbent suppliers such as 3DX-ray Ltd) and kinetic depth systems (developed and marketed through Astrophyscis Inc) as 3rd party solutions. We have a clear focus on medical systems and we are currently part of a consortium recentlly awarded an EPSRC grant on Point-of-Care High Accuracy Fracture Risk Prediction. This is an exciting project and we look forward to working with our partners in developing HALO technology for this market. | Corporate Round / Jul 20, 2026 | ||
| Silicon Microgravity Limited is a spin-out from Cambridge University. The underpinning sensor technology was developed through a collaboration with BP plc and provides a breakthrough in the management of oil and gas reservoirs. The technology has been developed in Cambridge University’s Nanoscience Centre primarily funded by BP and Innovate UK. | $8.1M / Venture - Series Unknown / Jul 16, 2026 | ||
| Luffy AI uses Adaptive Intelligence to evolve robotic control systems. | $10.8M / Series A / Jul 07, 2026 | ||
| Revolver Therapeutics develops peptide therapeutics that target transcription factors to create new routes to cancer treatment. The company uses a proprietary peptide discovery and screening platform, including its Transcription Block Survival technology, to identify functional peptide inhibitors in live cell systems. This platform enables rapidscreening of large peptide libraries and enrichment of molecules that functionally block or modulate transcription factor activity. Revolver Therapeutics focuses on translating its peptide-based transcription factor screening technology into therapeutic candidates for oncology. Its work is based on research spun out from the University of Bath and is aimed at generating next-generation peptide drugs for difficult-to-treat cancers. | $764K / Pre-Seed / Jul 03, 2026 | ||
| Silveray develop affordable large-area direct conversion detectors for the X-ray imaging market. | $6.6M / Series A / Jun 17, 2026 | ||
| See all 151 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does UK Innovation & Science Seed Fund invest in?
UK Innovation & Science Seed Fund invests primarily in Biotechnology, Health Care and Medical startups, most often at Seed and Venture - Series Unknown stage. Most of the 151 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does UK Innovation & Science Seed Fund invest in?
UK Innovation & Science Seed Fund typically joins rounds of $582k–$5.9M at Seed and $1M–$6.7M at Venture - Series Unknown. These are whole funding-round sizes, not UK Innovation & Science Seed Fund's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds UK Innovation & Science Seed Fund took part in.
How do I contact UK Innovation & Science Seed Fund?
Public channels for UK Innovation & Science Seed Fund include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at UK Innovation & Science Seed Fund?
The team at UK Innovation & Science Seed Fund includes Alexander Leigh (Investment Director), Andrew Muir (Investment Director & Fund Principal) and Mark White (Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
